Positions for Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

In Q3 2018 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) big money sentiment decreased to 1.14, SEC filings reveal. That’s down -0.05, from 2018Q2’s 1.19. 242 funds opened new and increased equity positions, while 212 sold and reduced equity positions in Regeneron Pharmaceuticals Inc so the sentiment worsened. Funds own 70.41 million shares, up from 70.25 million shares in 2018Q2. Funds holding Regeneron Pharmaceuticals Inc in top 10 decreased from 8 to 7 for a decrease of 1. In total 39 funds closed positions, 173 reduced and 153 increased. Also 89 funds bought new Regeneron Pharmaceuticals Inc stakes.

Significant Regeneron Pharmaceuticals Inc Shareholders

Hellman Jordan Management Co Inc Ma owns 35,000 shares in Regeneron Pharmaceuticals Inc as of Q3 2018. As of Q3 2018, 57,431 shares of Regeneron Pharmaceuticals Inc are owned by Lagoda Investment Management L.P.. Moreover, Healthcor Management L.P. reported 400,000 shares in Regeneron Pharmaceuticals Inc equivalent to 5.36% of its portfolio. Sustainable Growth Advisers Lp revealed 995,737 shares position in Regeneron Pharmaceuticals Inc. The California-based fund Mcdonald Capital Investors Inc Ca holds 104,535 shares or 3.5% of their portfolio.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide.The firm is valued at $46.13 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s.19.91 is the P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

REGN is touching $423.97 during the last trading session, after increased 2.17%.Regeneron Pharmaceuticals, Inc. has volume of 700,044 shares. Since February 16, 2018 REGN has risen 1.07% and is uptrending. REGN outperformed the S&P500 by 1.07%.

Goldman Sachs Gru has invested 0.06% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Sumitomo Life Ins holds 5,054 shs. Jefferies Gru Limited invested in 0% or 552 shs. New York State Common Retirement Fund stated it has 0.1% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Griffin Asset Management Inc invested in 4,488 shs or 0.27% of the stock. Virtu Ltd Liability Corp stated it has 583 shs or 0% of all its holdings. Yorktown Management Research reported 700 shs. Gotham Asset Mgmt Limited Com owns 11,996 shs for 0.07% of their capital. Tiaa Cref Mngmt holds 0.05% of its capital in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 201,460 shs. Loomis Sayles & Ltd Partnership reported 2.65% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Stephens Incorporated Ar accumulated 9,027 shs or 0.09% of the stock. Cibc Ww owns 23,989 shs or 0.08% of their US capital. First Republic Inv Mngmt Inc reported 8,648 shs. California State Teachers Retirement has invested 0.1% of its capital in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Moreover, Invest House Limited Com has 0.08% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Regeneron Pharmaceuticals, Inc. registered $47.14 million net activity with 0 insider buys and 8 sales since August 22, 2018. Another trade for 1,791 shs valued at $734,310 was made by GOLDSTEIN JOSEPH L on Thursday, January 10. On Thursday, September 6 Shares for $42.52 million were sold by Sanofi. VAGELOS P ROY sold 6 shs worth $2,294. Fenimore Christopher R. also sold $663,381 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Wednesday, December 19.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Ratings Coverage

Total analysts of 5 have positions in Regeneron Pharmaceuticals (NASDAQ:REGN) as follows: 2 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 40%. Since October 1, 2018 according to StockzIntelligence Inc Regeneron Pharmaceuticals has 5 analyst reports. On Thursday, October 11 the stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Equal-Weight” rating given by Morgan Stanley. In Thursday, October 11 report Canaccord Genuity maintained the stock with “Hold” rating. The stock rating was upgraded by Guggenheim to “Buy” on Friday, January 4. On Friday, December 14 the rating was upgraded by Goldman Sachs to “Buy”.

For more Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news published briefly go to: Nasdaq.com, Streetinsider.com, , Seekingalpha.com or Nasdaq.com. The titles are as follows: “Why Regeneron (REGN) Might Surprise This Earnings Season – Nasdaq” published on November 05, 2018, “Regeneron (REGN) Announces 1-Yr. Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium – StreetInsider.com” on February 11, 2019, “The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon’s Diabetes Drug – Yahoo Finance” with a publish date: January 18, 2019, “European advisory group backs CV benefit claim for Sanofi’s Praluent – Seeking Alpha” and the last “Notable ETF Outflow Detected – IBB, BIIB, ILMN, REGN – Nasdaq” with publication date: February 14, 2019.